Australia's most trusted
source of pharma news
Posted 10 May 2022 PM
Gilead may yet secure a PBS berth for Vemlidy with PBAC adding the Hepatitis B treatment to its agenda for a second time as it attempts to clear out positive recommendations not taken up by sponsors.
Vemlidy was recommended back in March 2017, but Gilead has previously urged that the PBAC's choice of the lowest comparator results in a "commercially unviable price". It has now been sitting on the wait list for more than five years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.